$2.50 -0.04 (%) Protalix BioTherapeutics Inc - AMEX

Sep. 19, 2014 | 04:00 PM

Partner Headlines

  1. UPDATE: Protalix Shares Spike Higher on FDA Approval of Pediatric Indication for ELELYSO(TM) for Injection, for IV Use for Treatment of Type 1 Gaucher Disease

    Benzinga | Aug. 28, 2014 | 13:18PM EST
  2. 3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology

    Benzinga | Aug. 24, 2014 | 20:08PM EST
  3. Stocks Hitting 52-Week Lows

    Benzinga | Jul. 1, 2014 | 10:20AM EST
  4. Facebook Leads 3 High-Volume Young Gun Stock Leaders

    IBD | Jun. 24, 2014 | 19:14PM EST
  5. Protalix Biotherapeutics Reports New Data on ELELYSO, Oral GCD Will Be Presented at European Working Group on Gaucher Disease

    Benzinga | Jun. 23, 2014 | 07:35AM EST
  6. Protalix Offers Update on Health Canada Evaluation, Says Manufacturing Facility Utilizing ProCellEx Deemed Acceptable by EMA, FDA, IMH, ANVISA, TGA

    Benzinga | Jan. 23, 2014 | 16:35PM EST
  7. Protalix Reports Oral GCD Well Toleratead, Active Enzyme Detected in Blood

    Benzinga | Oct. 14, 2013 | 07:31AM EST
  8. Protalix BioTherapeutics Announces Proposed $60M Offering of Convertible Notes

    Benzinga | Sep. 11, 2013 | 16:07PM EST
  9. Protalix Says New Clinical Data on ELELYSO Will Be Presented at WORLD Symposium

    Benzinga | Feb. 13, 2013 | 00:33AM EST
  10. Benzinga's M&A Chatter for Tuesday February 5, 2013

    Benzinga | Feb. 5, 2013 | 10:48AM EST
  11. Mid-Afternoon Market Update: Markets Edge Toward Record Highs, Arch Coal Falls Further

    Benzinga | Feb. 5, 2013 | 08:57AM EST
  12. Mid-Day Market Update: Markets Rally Further, Clean Harbors Drops on CFO Controversy

    Benzinga | Feb. 5, 2013 | 06:33AM EST
  13. Protalix Says Reviewing Partnering, Other Alternatives

    Benzinga | Feb. 5, 2013 | 04:48AM EST
  14. Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO

    Benzinga | Dec. 6, 2012 | 00:49AM EST
  15. Protalix BioTherapeutics Inc Reports Operating Results (10-Q)

    GuruFocus | Nov. 8, 2012 | 03:36AM EST
  16. Protalix BioTherapeutics Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients With PRX-102

    Benzinga | Aug. 13, 2012 | 01:47AM EST
  17. Protalix BioTherapeutics Inc Reports Operating Results (10-Q)

    GuruFocus | Aug. 3, 2012 | 14:25PM EST
  18. Benzinga's Downgrade Summary for June 25, 2012

    Benzinga | Jun. 25, 2012 | 09:29AM EST
  19. Ryder System, Associated Estates Realty Corporation Among Stocks Down on High Volume Friday

    FoxBusiness | Jun. 22, 2012 | 06:33AM EST
  20. Ryder System, Protalix BioTherapeutics Gapping Down Friday

    FoxBusiness | Jun. 22, 2012 | 04:31AM EST
  21. Protalix BioTherapeutics (PLX) Gains 18% After FDA Approval

    MarketIntelligenceCenter | May. 2, 2012 | 09:53AM EST
  22. Protalix BioTherapeutics Inc Reports Operating Results (10-K)

    GuruFocus | Feb. 27, 2012 | 10:14AM EST
  23. Notable Call Options Activity in Protalix BioTherapeutics

    Benzinga | Feb. 17, 2012 | 06:46AM EST
  24. Protalix BioTherapeutics Announces the Pricing of Public Offering of Common Stock

    Benzinga | Feb. 16, 2012 | 01:41AM EST
  25. Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock; No Amount Given

    Benzinga | Feb. 15, 2012 | 09:16AM EST
  26. FDA Delays Protalix's Drug Decision; Investors Feel Sick

    Benzinga | Dec. 31, 0000 | 19:00PM EST
Trading Center